Liraglutide on TikTok: What @dr.dam.glp1 is likely getting right and wrong

What's this video probably claiming?

Based on the caption and context, @dr.dam.glp1 is likely walking Spanish-speaking viewers through how liraglutide works, possibly covering injection technique, dosing schedules, and its uses in type 2 diabetes and weight management. The creator identifies as an internist, so the framing is probably clinical enough to sound authoritative. The "no es comercial pagado" disclaimer suggests they're positioning this as independent education, which is a reasonable thing to note but doesn't automatically mean the information is complete or current. Liraglutide (brand names Victoza for diabetes, Saxenda for obesity) was the dominant GLP-1 before semaglutide and tirzepatide took over the headlines. That context matters, because some of what's "known" about liraglutide on social media is either outdated or extrapolated incorrectly from newer agents.

What does the science actually show?

Liraglutide's evidence base is genuinely solid. The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, NEJM) showed that 3.0 mg daily produced 8.4% mean weight loss versus 2.8% with placebo over 56 weeks. That's meaningful but lower than what semaglutide 2.4 mg achieves in the STEP trials (roughly 14.9% per Wilding et al., 2021, NEJM). For diabetes, the LEADER trial (Marso et al., 2016, NEJM) showed liraglutide 1.8 mg reduced major adverse cardiovascular events by 13% in high-risk type 2 diabetics. So the drug works, the cardioprotective signal is real, and the mechanism, stimulating glucose-dependent insulin secretion and suppressing glucagon, is well understood. What social media frequently glosses over is that liraglutide requires daily subcutaneous injection, which affects real-world adherence compared to once-weekly semaglutide.

Where does the social media noise diverge from clinical reality?

Several predictable distortions tend to appear in liraglutide content. First, creators often present it as interchangeable with semaglutide or tirzepatide. It is not. These are different molecules with different receptor binding profiles, dosing frequencies, and clinical outcomes. Second, "how to use" videos sometimes blur into implicit dosing guidance, which is a regulatory problem regardless of a creator's credentials. Third, liraglutide's tolerability profile, particularly GI side effects affecting 20-40% of users in clinical trials, tends to get minimized in enthusiastic walkthrough videos. Davies et al. (2015, Lancet Diabetes and Endocrinology) documented nausea in roughly 39% of participants at the 3.0 mg dose. Fourth, content in Spanish targeting non-US audiences sometimes omits that access, storage requirements (2-8 degrees Celsius), and compounded versions raise entirely separate questions about quality and consistency that do not apply to brand-name Victoza or Saxenda.

What should you actually know?

Liraglutide is a legitimate, FDA-approved medication with over a decade of post-market safety data. But "legitimate" does not mean appropriate for everyone or easily self-managed based on a TikTok video. The titration schedule exists for a reason: starting at 0.6 mg daily and increasing weekly toward therapeutic doses reduces but does not eliminate GI side effects. Pancreatitis risk, though statistically rare in trials, remains a labeled warning. Thyroid C-cell tumor risk observed in rodent studies has not been confirmed in humans but carries a black box warning. Any creator walking through "how to use" liraglutide should be pairing that with explicit guidance to work with a licensed prescriber, not as a disclaimer throwaway but as the actual point. If this video does otherwise, that's where it departs from responsible clinical communication, regardless of the creator's credentials.